What are the primary medications for pseudobulbar affect (PBA)?
The main medication used to treat pseudobulbar affect (PBA) is Nuedexta, which is a combination of dextromethorphan and quinidine [1].
What is Nuedexta used for?
Nuedexta is prescribed to manage emotional lability associated with neurological conditions such as stroke and amyotrophic lateral sclerosis (ALS) [1]. Emotional lability, also known as pseudobulbar affect (PBA), is characterized by frequent, involuntary, and exaggerated emotional expression, such as crying or laughing, that may not align with the person's internal feelings [2].
What are the potential alternatives to Nuedexta for PBA?
While Nuedexta is the only FDA-approved medication specifically for PBA, other approaches and medications are sometimes considered or investigated off-label. Research into alternative treatments for PBA is ongoing [3].
How does quinidine in Nuedexta work?
Quinidine is an enzyme inhibitor that increases the concentration of dextromethorphan in the brain. Dextromethorphan is believed to work by affecting the activity of glutamate, a neurotransmitter involved in brain pathways that control emotional expression [1][4].
What is the general outlook for PBA treatment?
The treatment landscape for PBA is evolving, with ongoing research aiming to identify new therapeutic targets and refine existing treatments. Patient and caregiver support remains a crucial aspect of managing PBA [3].